Shattuck Labs (STTK) Net Income towards Common Stockholders (2019 - 2026)
Shattuck Labs (STTK) reported Net Income towards Common Stockholders of -$14.8 million for Q1 2026, down 7.78% year-over-year from -$16.0 million in Q1 2025, and down 10.43% on a QoQ basis from -$13.4 million in Q4 2025.
Shattuck Labs (STTK) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$14.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 7.78% year-over-year to -$14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.9 million (up 30.1% YoY) and the FY2025 annual result came in at -$48.8 million, up 35.27% from the prior year.
- Net Income towards Common Stockholders declined to -$14.8 million in Q1 2026 per STTK's latest filing, from -$13.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$10.7 million in Q3 2025 and bottomed at -$28.6 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$20.0 million (2024), against an average of -$20.1 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders plunged 431.6%; it then surged 43.25% in 2025.
- Tracing STTK's Net Income towards Common Stockholders over 5 years: stood at -$26.3 million in 2022, then advanced by 27.88% to -$19.0 million in 2023, then dropped by 3.64% to -$19.6 million in 2024, then soared by 31.92% to -$13.4 million in 2025, then decreased by 10.43% to -$14.8 million in 2026.
- Per Business Quant, the three latest STTK Net Income towards Common Stockholders figures stand at -$14.8 million (Q1 2026), -$13.4 million (Q4 2025), and -$10.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Shattuck Labs | 667.80 Mn | 667.80 Mn | - | -14.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -10.72 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -19.64 Mn |
| Sep 30, 2024 | -17.92 Mn |
| Jun 30, 2024 | -22.96 Mn |
| Mar 31, 2024 | -20.04 Mn |
| Dec 31, 2023 | -18.95 Mn |
| Sep 30, 2023 | -28.60 Mn |
| Jun 30, 2023 | -22.75 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | -26.28 Mn |
| Sep 30, 2022 | -25.23 Mn |
| Jun 30, 2022 | -27.66 Mn |
| Mar 31, 2022 | -24.17 Mn |
| Dec 31, 2021 | 7.92 Mn |
| Sep 30, 2021 | -17.33 Mn |
| Jun 30, 2021 | -23.51 Mn |
| Mar 31, 2021 | -11.73 Mn |
| Dec 31, 2020 | -11.94 Mn |
| Sep 30, 2020 | -11.75 Mn |
| Jun 30, 2020 | -6.18 Mn |
| Mar 31, 2020 | -6.51 Mn |
| Dec 31, 2019 | -7.34 Mn |
| Sep 30, 2019 | -7.25 Mn |